Literature DB >> 17367606

Fibrolamellar carcinomas show overexpression of genes in the RAS, MAPK, PIK3, and xenobiotic degradation pathways.

Rajesh Kannangai1, Perumal Vivekanandan, Francisco Martinez-Murillo, Michael Choti, Michael Torbenson.   

Abstract

Fibrolamellar carcinomas (FLC) are a rare type of primary hepatocellular carcinoma found in younger individuals. FLC are known to have relatively few consistent chromosomal alterations, although a gain of chromosome 1q has been reported. The gene expression of 4 FLC (2 primary FLC and 2 metastatic deposits) were studied using Affymetrix DNA microarray technology (Santa Clara, CA). Selected genes were confirmed by real-time polymerase chain reaction. Relatively few genes were significantly overexpressed-447 genes, case 1; 1298 genes, case 2-corresponding to approximately 0.8% and 2.3%, respectively, of the 56000 transcripts present in the arrays. Of these, 155 genes were overexpressed simultaneously by both tumors. The number of significantly overexpressed genes more than doubled in the 2 metastatic deposits (2777 and 2855 genes compared with 1298 in the primary tumor). Proteins involved in the RAS, MAPK, PIK3, and xenobiotic degradation pathways were commonly overexpressed. Because chromosome 1q is thought to contain an important oncogene, additional attention was focused on this region. Of 114 total genes found overexpressed in common among all primary and metastatic tumors, 11 of 114 genes were located on chromosome 1q: ARF1, CD46, CNIH4, ENSA, FH, NICE-3, PSMB4, RGS2, RGS5, TIMM17A, and UFC1. Primary FLC show overexpression of genes involved in the RAS, MAPK, PIK3, and xenobiotic degradation pathways. Eleven common genes were consistently overexpressed on chromosome 1q among all tumors and metastases and warrant further study as potential oncogenes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367606     DOI: 10.1016/j.humpath.2006.07.019

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  24 in total

1.  A young woman with liver cancer.

Authors:  Celina S Ang; Richard K Do; Ali Shamseddine; Eileen M O'Reilly; Ali Haydar; Ashwaq Al-Olayan; Walid Faraj; Fouad Boulos; Mohamed Naghy; Dorothy Makanjoula; Hassan Farran; Hassan Sibai; David Wehbe; David P Kelsen; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

2.  Transcriptomic characterization of fibrolamellar hepatocellular carcinoma.

Authors:  Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-21       Impact factor: 11.205

3.  Genomic analysis of fibrolamellar hepatocellular carcinoma.

Authors:  Lei Xu; Florette K Hazard; Anne-Flore Zmoos; Nadine Jahchan; Hassan Chaib; Phillip M Garfin; Arun Rangaswami; Michael P Snyder; Julien Sage
Journal:  Hum Mol Genet       Date:  2014-08-13       Impact factor: 6.150

4.  DNAJB1-PRKACA fusion kinase interacts with β-catenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma.

Authors:  Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-21       Impact factor: 11.205

5.  mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma.

Authors:  Kimberly J Riehle; Matthew M Yeh; Jeannette J Yu; Heidi L Kenerson; William P Harris; James O Park; Raymond S Yeung
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

6.  Molecular characteristics of fibrolamellar hepatocellular carcinoma.

Authors:  Attila Patonai; Boglárka Erdélyi-Belle; Anna Korompay; Aron Somorácz; Péter Törzsök; Ilona Kovalszky; Tamás Barbai; Erzsébet Rásó; Gábor Lotz; Zsuzsa Schaff; András Kiss
Journal:  Pathol Oncol Res       Date:  2012-08-08       Impact factor: 3.201

7.  Unique genomic profile of fibrolamellar hepatocellular carcinoma.

Authors:  Helena Cornella; Clara Alsinet; Sergi Sayols; Zhongyang Zhang; Ke Hao; Laia Cabellos; Yujin Hoshida; Augusto Villanueva; Swan Thung; Stephen C Ward; Leonardo Rodriguez-Carunchio; Maria Vila-Casadesús; Sandrine Imbeaud; Anja Lachenmayer; Alberto Quaglia; David M Nagorney; Beatriz Minguez; Flair Carrilho; Lewis R Roberts; Samuel Waxman; Vincenzo Mazzaferro; Myron Schwartz; Manel Esteller; Nigel D Heaton; Jessica Zucman-Rossi; Josep M Llovet
Journal:  Gastroenterology       Date:  2014-12-31       Impact factor: 22.682

8.  Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium.

Authors:  Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa
Journal:  Gastrointest Cancer Res       Date:  2013-01

9.  A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.

Authors:  Imane El Dika; Robert J Mayer; Alan P Venook; Marinela Capanu; Michael P LaQuaglia; Rachel Kobos; Allison F O'Neill; Joanne F Chou; Michele Ly; Celina Ang; Eileen M O'Reilly; John D Gordan; Ghassan K Abou-Alfa
Journal:  Oncologist       Date:  2020-05-26

10.  Anterior gradient-2 is overexpressed by fibrolamellar carcinomas.

Authors:  Perumal Vivekanandan; Shien T L Micchelli; Michael Torbenson
Journal:  Hum Pathol       Date:  2008-10-29       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.